[1]雍文穆,邓淑娇,李 森.异丙托溴胺联合布地奈德福莫特罗粉治疗中度慢性阻塞性肺病疗效及对患者肺功能的影响研究*[J].陕西医学杂志,2020,49(3):349-352,356.
　YONG Wenmu,DENG Shujiao,LI Sen..Effect of ipratropium bromide combined with budesonide formoterol powder on patients with moderate chronic obstructive pulmonary disease and its effect on pulmonary function[J].,2020,49(3):349-352,356.
点击复制

异丙托溴胺联合布地奈德福莫特罗粉治疗中度慢性阻塞性肺病疗效及对患者肺功能的影响研究*
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
49
期数:
2020年3期
页码:
349-352,356
栏目:
药物与临床
出版日期:
2020-03-05

文章信息/Info

Title:
Effect of ipratropium bromide combined with budesonide formoterol powder on patients with moderate chronic obstructive pulmonary disease and its effect on pulmonary function
文章编号:
DOI:〖HT5K〗10.3969/j.issn.10007377.2020.03.022
作者:
雍文穆; 邓淑娇; 李 森
陕西省汉中市中心医院呼吸与危重症医学科(汉中723000)
Author(s):
YONG Wenmu; DENG Shujiao; LI Sen.
Department of Respiratory and Critical Care Medicine,Hanzhong Central Hospital(Hanzhong 723000)
关键词:
复方异丙托溴胺;  慢性阻塞性肺病;  布地奈德福莫特罗;  肺功能
Keywords:
Ipratropium bromide;  Chronic obstructive pulmonary disease;  Budesonide formoterol;  Pulmonary function
分类号:
R563.3
文献标志码:
A
摘要:
目的:探究异丙托溴胺联合布地奈德福莫特罗粉治疗中度慢性阻塞性肺病的效果及对患者肺功能的影响。方法:选取中度慢性阻塞性肺病患者100例,按照完全随机法将所有患者分为对照组和联合用药组各50例。对照组使用布地奈德福莫特罗粉吸入剂,联合用药组使用复方异丙托溴铵溶液联合布地奈德福莫特罗粉吸入剂进行治疗。使用肺功能检测仪检测FEV1、FVC,使用酶联免疫吸附试验法检测血清C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6),使用全自动生化分析仪来检测血胆固醇、低密度蛋白。使用ABL90FLEX血气分析仪检测血氧分压(PaO2)、动脉血二氧化碳分压(PaCO2),观察两组各实验室指标并对比治疗效果及不良反应。结果:治疗后联合用药组对CRP、TNF-α、IL-6、血胆固醇、低密度蛋白、PaCO2因子的降低作用显著高于对照组,PaO2表达水平高于对照组(P<0.05)。联合用药组的总有效率高于对照组(P<0.05)。联合用药组的不良反应高于对照组(P<0.05)。结论:复方异丙托溴铵溶液联合布地奈德福莫特罗粉吸入剂可有效的抑制慢性阻塞性肺病患者肺部炎症,改善患者临床症状,促进患者恢复,效果较好。
Abstract:
Objective:To explore the effect of ipratropium bromide combined with budesonide formoterol powder in the treatment of moderate chronic obstructive pulmonary disease(COPD)and its effect on pulmonary function. Methods:100 patients with moderate COPD were randomly divided into control group and combined group,with 50 cases in each group. The control group was treated with budesonide formoterol powder inhalation,and the combined group was treated with compound ipratropium bromide solution and budesonide formoterol powder inhalation. FEV1 and FVC were detected by lung function detector. Serum C reactive protein(CRP),tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6)were detected by enzyme linked immunosorbent assay. Serum cholesterol and low-density protein were detected by automatic biochemical analyzer. The blood oxygen partial pressure(PaO2)and arterial carbon dioxide partial pressure(PaCO2)were measured by ABL90FLEX blood gas analyzer. The laboratory indexes of the two groups were observed. The therapeutic effect and adverse reactions were compared between the two groups. Results:After treatment,the decrease of CRP,TNF-α,IL-6,blood cholesterol,low-density protein and PaCO2 in the combined group was significantly higher than that in the control group,and the level of PaO2 was higher than that in the control group(P<0.05). The total effective rate of the combined group was higher than that of the control group(P<0.05). The adverse reactions in the combined group were higher than those in the control group(P<0.05). Conclusion:The combination of compound ipratropium bromide solution and budesonide formoterol powder inhalation can effectively inhibit the pulmonary inflammation,improve the clinical symptoms and promote the recovery of patients with COPD.

参考文献/References:

[1] 赖玉田,苏建华,杨 梅,等.术前短期综合肺康复训练对肺癌合并轻中度慢性阻塞性肺病患者的影响:一项前瞻性随机对照试验[J].中国肺癌杂志,2016,19(11):746-753.
[2] 傅元冬,朱桂松.健脾补肾法治疗轻中度慢性阻塞性肺疾病稳定期患者47例[J].环球中医药,2016,9(9):1114-1116.
[3] 张永庆,苗 毅,尚立群,等.布地奈德福莫特罗联合噻托溴铵治疗中重度慢阻肺稳定期疗效观察[J].陕西医学杂志,2016,45(4):494-495.
[4] 强光亮,余其多,梁朝阳,等.慢性阻塞性肺疾病对非小细胞肺癌术后复发风险的影响[J].中国肺癌杂志,2018,21(3):215-220.
[5] 王浩凌,唐永江,徐大敏,等.慢性阻塞性肺病炎性因子(CRP、TNF-α、IL-6)与冠脉造影Gensini评分相关性研究[J].医学影像学杂志,2016,26(7):1230-1231,1236.
[6] 张鹏鹏,辛晓峰,何 骞,等.慢性阻塞性肺病患者巨噬细胞功能与受体表达的关系研究[J].现代生物医学进展,2017,17(20):3864-3867,3896.
[7] Walsh JR,Pegg J,Yerkovich ST,et al. Longevity of pulmonary rehabilitation benefit for chronic obstructive pulmonary disease-health care utilisation in the subsequent 2 years[J]. BMJ Open Respir Res, 2019,6(1):e000500.
[8] Mtisi TF,Frishman WH. Beta adrenergic blocker use in patients with chronic obstructive pulmonary disease and concurrent chronic heart failure with a low ejection fraction[J].Cardiol Rev, 2020,28(1):20-25.
[9] Yu XQ,Yang SG,Li H,et al. Preliminary study to evaluate three different treatments on stable chronic obstructive pulmonary disease patients based on markov model[J]. Evid Based Complement Alternat Med,2019,17:6478926.
[10] 李前前,邱丹丹,张伶俐.多索茶碱联合复方异丙托溴铵溶液对老年慢性阻塞性肺病患者血气分析的影响[J].贵州医药,2018,42(12):1436-1438.
[11] 耿慧琴,唐学义.复方异丙托溴铵液用于慢阻肺急性加重期的疗效[J].医药论坛杂志,2015,36(9):160-161.
[12] 李志强.布地奈德福莫特罗、沙美特罗替卡松吸入治疗缓解期慢性阻塞性肺病的效果、安全性及生存质量对比研究[J].贵州医药,2019,43(4):553-555.
[13] 李 研,佟 飞,米 香.布地奈德福莫特罗粉吸入剂联合噻托溴铵粉吸入剂治疗ACOS的疗效及其对患者血清hs-CRP、EOS的影响[J].海南医学,2017,28(18):2997-3000.
[14] 王 敏,陈 阁.清热化痰祛瘀方联合西药治疗慢性阻塞性肺疾病急性加重期患者的临床研究[J].陕西中医,2019,40(5):610-612.
[15] 刘志刚,童金生,吴柱国,等.噻托溴铵联合茶碱对慢性阻塞性肺疾病患者IL-6、hs-CRP、TNF-α、CK-MB和肺功能的影响研究[J].重庆医学,2019,48(5):863-865,869.
[16] 王东杰.急性心肌梗死患者IL-6、TNF-α、INF-γ、VEGF、Fg、hs-CRP水平变化及其与介入治疗关系的研究[J].国际检验医学杂志,2019,40(6):750-753.
[17] 刘宪河.支气管肺炎患儿血清hs-CRP、IL-6和TNF-α水平变化及临床意义[J].河北医药,2019,41(1):99-102.
[18] 刘 芳,刘义庆,成士清,等.济南地区不同性别、年龄人群血清小而密低密度脂蛋白胆固醇水平调查[J].广西医学,2018,40(17):2018-2019,2037.
[19] 邹世辉,徐惠绵,黄宝俊.术前PaO2、PaCO2、PT、Fg、APTT和胃肠癌术后肺栓塞的关系以及肺栓塞的发生时间[J].现代肿瘤医学,2019,27(5):805-808.
[20] 李焕根,陈伟文,黄幼佩.纤维支气管镜与肺泡灌洗术对老年重症肺部感染患者治疗前后PaO2、PaCO2、SpO2及pH指标变化的影响[J].中国老年学杂志,2017,37(23):5871-5873.

备注/Memo

备注/Memo:
*四川省卫生和计划生育委员会科研课题(115784152)
更新日期/Last Update: 2020-03-25